Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Net Income: 2023-2025

Historic Net Income for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$43.7 million.

  • CG Oncology's Net Income fell 114.22% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 107.99%. This contributed to the annual value of -$88.0 million for FY2024, which is 81.36% down from last year.
  • Per CG Oncology's latest filing, its Net Income stood at -$43.7 million for Q3 2025, which was down 5.52% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Net Income registered a high of -$8.7 million during Q1 2023, and its lowest value of -$43.7 million during Q3 2025.
  • Moreover, its 3-year median value for Net Income was -$18.9 million (2024), whereas its average is -$23.3 million.
  • Data for CG Oncology's Net Income shows a maximum YoY crashed of 119.05% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Net Income stood at -$16.6 million in 2023, then crashed by 92.16% to -$31.8 million in 2024, then crashed by 114.22% to -$43.7 million in 2025.
  • Its Net Income was -$43.7 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$34.5 million in Q1 2025.